MedTrace Logo

ACT MALI: Treatment of Malaria Based on Combination Therapies

NCT00452907 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 780

Last updated 2010-02-17

No results posted yet for this study

Summary

Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated falciparum malaria and malaria attributable anemia

Conditions

Interventions

DRUG

Artesunate

oad, per os, 3 days of treatment

DRUG

Artesunate + Sulfadoxine-Pyrimethamine

oad, per os

DRUG

arthemether + lumefantrine

bid, per os. Duration of treatment: 3 days

Sponsors & Collaborators

Principal Investigators

  • Valérie Lameyre · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Mali

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00452907 on ClinicalTrials.gov